Ani Pharmaceuticals (ANIP) EPS (Weighted Average and Diluted) (2016 - 2026)
Ani Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 16 years, with the latest figure at $1.17 for Q4 2025.
- On a quarterly basis, EPS (Weighted Average and Diluted) rose 312.73% to $1.17 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.35, a 393.86% increase, with the full-year FY2025 number at $3.32, up 419.23% from a year prior.
- EPS (Weighted Average and Diluted) hit $1.17 in Q4 2025 for Ani Pharmaceuticals, up from $1.13 in the prior quarter.
- Over the last five years, EPS (Weighted Average and Diluted) for ANIP hit a ceiling of $1.17 in Q4 2025 and a floor of -$1.87 in Q4 2021.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.17 across 5 years, with a median of -$0.06 in 2021.
- Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 12800.0% in 2022 and later soared 1266.67% in 2024.
- Tracing ANIP's EPS (Weighted Average and Diluted) over 5 years: stood at -$1.87 in 2021, then surged by 84.49% to -$0.29 in 2022, then surged by 106.9% to $0.02 in 2023, then tumbled by 2850.0% to -$0.55 in 2024, then soared by 312.73% to $1.17 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for ANIP at $1.17 in Q4 2025, $1.13 in Q3 2025, and $0.36 in Q2 2025.